Teva Canada Announces the Launch of Teva-Cyclosporine® Ophthalmic Emulsion, the First Generic Version of Restasis® in Canada for the Treatment of Dry Eye Disease
Five Things Facing Teva's New CEO Richard Francis :: Generics Bulletin
Teva Gets a Head Start Over Rivals With Launch of HIV Generics; Analyst Says 'Buy'
Teva Canada Announces the Launch of Teva-Cyclosporine® Ophthalmic Emulsion, the First Generic Version of Restasis® in Canada for the Treatment of Dry Eye Disease
Generic Restasis Availability - Drugs.com
Allergan pushes FDA to defend Restasis from early generics | Fierce Pharma
Allergan settles with one of four companies contesting Restasis patent | Reuters
Mylan: Did The FDA Clear The Runway For Generic Restasis? (NASDAQ:VTRS) | Seeking Alpha
Restasis Coupon, Cost & Discount Savings - PricePro Pharmacy
Allergan loses Restasis patent protections in federal court decision | Fierce Pharma
Tags search | Ctech
Controversy Over Restasis Patents is Misplaced - IPWatchdog.com | Patents & Intellectual Property Law
Restasis (cyclosporine): Side effects, dosage, and more
Teva
FDA Approves First Generic Formulation of Restasis - Eyewire+
US FTC disputes over 100 medical patents listed with FDA including asthma inhalers | Reuters
Surprise! Viatris Proves Its Worth With First Generic Restasis Approval :: Generics Bulletin
In a New Twist in Restasis Legal Battle, Teva Sues the FDA
Dear Cyclosporine ANDA Applicants Letter
FDA Approves Vuity, the First Eye Drop to Treat Presbyopia - Eyewire+
FDA Approves Restasis Generic for Dry Eye - GoodRx
US federal judge invalidates Allergan patents on Restasis - Pharmaceutical Business review
FDA Fires Back Over Teva Suit on Restasis 180 Days of Exclusivity | RAPS
Teva - Pharma
UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA ) TEVA PHARMACEUTICALS
FDA Issues Contamination Warnings for Two MSM Eye Drops - Eyewire+
